Drug interactions between cannabis and pediatric cancer medications

This review examines potential drug-drug interactions between cannabinoids and 25 common pediatric cancer medications, a critical concern as interest in cannabinoids for supportive care in children grows. The researchers stratified these antineoplastic agents into low, medium, and high interaction risk categories, identifying seven medications at high risk: cyclophosphamide, doxorubicin, etoposide, ifosfamide, irinotecan, vinblastine, and vincristine. The primary mechanisms of concern include inhibition of cytochrome P450 enzymes and UDP-glucuronosyltransferases, which could alter how the body metabolizes cancer drugs, as well as effects on drug transporters like P-glycoprotein and breast cancer resistance protein.

Importantly, the review also highlights emerging evidence of synergistic effects between cannabinoids and certain antineoplastic agents such as temozolomide, vinblastine, vinorelbine, and irinotecan—suggesting that in some cases, combined use might actually enhance therapeutic effects. However, a major gap remains: most pharmacokinetic data on cannabinoids come from adult studies, while children have developmental differences in drug metabolism and transporter expression. This mismatch underscores the urgent need for pediatric-specific safety, efficacy, and dosing studies to ensure cannabinoids can be safely integrated into pediatric cancer care protocols.

The findings have significant implications for families considering complementary cannabis-based treatments for pediatric cancer patients. Until rigorous pediatric trials are conducted, healthcare providers must carefully weigh potential benefits against interaction risks, particularly with high-risk chemotherapy agents.